Geron Announces Oral Presentation at European Hematology Association Congress
May 17, 2018 09:05 ET
|
Geron Corporation
MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been...
Geron to Present at the Needham Healthcare Conference
March 21, 2018 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
December 12, 2017 07:30 ET
|
Geron Corporation
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif., Dec. ...
Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
December 06, 2017 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take...
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
November 20, 2017 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3...
Geron Announces Presentations at American Society of Hematology Annual Meeting
November 01, 2017 09:05 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for...
Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
October 31, 2017 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to...
Geron Announces Updates to Imetelstat Clinical Development
July 31, 2017 19:00 ET
|
Geron Corporation
MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced updates to the clinical development plans for IMerge and IMbark, the ongoing trials of the...
Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
April 10, 2017 07:30 ET
|
Geron Corporation
Both IMerge and IMbark Continue in Lower Risk Myelodysplastic Syndromes and Relapsed or Refractory Myelofibrosis Conference Call Scheduled for 8:00 a.m. EDT Today, April 10 MENLO PARK, Calif.,...
Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results
March 01, 2017 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2016 and recent events. ...